Login or Register
Biomedical Learning Institute Taught by the Experts
Thought Leaders		 Biomedical Learning Institute
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
Co-Chairs
Dr. Bunn

Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director, USA
International Association for the Study of Lung
Cancer (IASLC)
Dr. Langer

Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group (RTOG)
Dr. Herbst

Roy S. Herbst, MD, PhD
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Smilow Cancer Hospital at Yale-New Haven
Yale School of Medicine
New Haven, CT
 

CME CREDIT INFORMATION

Release Date: 01/12/12

Expiration Date: 01/12/13


Physicians: maximum of 8 AMA PRA Category 1 Credit(s)™

Click here for resources from the Global Resource for Advancing Cancer Education (GRACE).

CME/CE-Accredited Webcasts, Presentation and Audio Downloads
Personalized Therapies and Best Clinical Practices for Lung Cancer

You may participate in any or all of the sessions for CME/CE credit or a Certificate of Attendance after you review the required ACCME (Accreditation Council on Continuing Medical Education) information on this page.
Menu
Overview and Faculty Disclosures >> Sessions >> Evaluation & Certificate
Overview of This CME/CE-Accredited Educational Activity
Your Options for Methods of Participation are:
  1. View any of the sessions online (PowerPoint Slides synced with the live activities audio)
  2. Download the PowerPoint Presentations
  3. Download session audio files as MP3s or podcasts
  4. Sessions can be individually reviewed for credit. You can participate in as few or as many as you desire.

Overview

The primary objective of this activity is to provide oncologists, hematologist/oncologists and allied healthcare professionals treating lung cancer patients with the knowledge and competence enabling them to close several very important Practice Gaps arising primarily from important data presented at the annual ASCO meeting in June 2010 and information identified from other sources, especially direct measurements: interviews and focus groups with clinicians treating lung cancer. This information will help enable clinicians to treat their patients with the optimal personalized approaches in order to improve patient outcomes and minimize drug-induced toxicities. This data will be supplemented, as needed, with additional data from the June 2011 ASCO meeting and from the other major meetings in 2011, including the 14th World Lung Cancer Conference in Amsterdam in July 2011, as well as from publications, and other data sources and interviews with academic experts and community-based oncologists.

Educational Statement of Need

The Biomedical Learning Institute (BMLI) has conducted a very extensive Practice Gap identification and Needs Assessment with the target audience of oncologists, hematologist/oncologists and allied healthcare professionals involved in the treatment, care and/or management of patients with lung cancer. The major Practice Gaps addressed in this activity are listed below.

  1. There is a practice gap between the community-based oncologists' knowledge and understanding of the new CAP/IASLC recommended guidelines for molecular biomarker tests and the roles of these tests in the NSCLC algorithm for therapy.
  2. There is a practice gap between the methodology used by academics and researchers and the methodology used in the community for devising treatment strategies for NSCLC patients across all lines of therapy.
  3. There is a practice gap between the fact that most community-based oncologists do not order the EGFR mutation tests before initial NSCLC therapy for the appropriate patients and the need to do this test almost routinely, at the very least for non-smokers or light smokers. This results in under treating mutation patients with the ideal therapy.
  4. The practice gap is that despite the FDA indication for pemetrexed for NSCLC patients with nonsquamous histology, and the warning against using bevacizumab for squamous histology, such critical histology testing is not being done routinely.
  5. There is a practice gap between what most community-based oncologists understand as to which drugs can be given safely at full doses to treat NSCLC and what the published literature reveals, especially with multi-targeted antifolate inhibition that is becoming an established gold standard for mutation-negative nonsquamous NSCLC.
  6. A practice gap exists because many community-based oncologists are not using regimens that inhibit angiogenesis where experts and clinical data support such usage as being the ideal practice.
  7. There is a practice gap between what community oncologists know and what academic oncologists know about treating EGFR-resistant NSCLC patients. The ideal, or more effective regimens or agents, including those adding to or replacing therapy solely targeting EGFR, are not being used by most community-based oncologists.
  8. There is a practice gap between what community oncologists do not know and what academic oncologists do know about the possibilities of enrolling lung cancer patients on clinical trials with three potentially highly active new chemotherapies.
  9. There is a practice gap that exists between conducting and not conducting Spiral CT scanning in heavy ex-smokers or current smokers versus only conducting conventional chest X-Rays. This practice will, no doubt, become more clearly defined prior to the September 2011 symposium, the subject of this grant request.
  10. There is a practice gap between which lung cancer trials are not known by and available to the community-based oncologists and those that are available for their patients that fail to respond to conventional therapies and are often ideal for their patients to benefit from such clinical trials.

List of Sessions

Session 1: RETHINKING THE NSCLC THERAPY PARADIGM
Chair: Corey Langer
1a.
The evolving algorithm for NSCLC: Moving beyond the traditional patient management to improve outcomes with new and emerging strategies.
Paul Bunn
1b.
How do we incorporate the new College of American Pathology /IASLC molecular biomarker testing guidelines into our routine NSCLC practices?
Philip Mack
1c.
Roundtable Panel Discussion and Q & A
Faculty and Learners
Session 2: PERSONALIZING EGFR-TARGETED THERAPY
Chair: Roy Herbst
2a.
Case Study: Personalizing therapy for NSCLC with EGFR inhibition strategies: The gold standard for outcomes.
Thomas Lynch (Talk given by Roy Herbst)
2b.
Case Study: Overcoming NSCLC resistance to EGFR inhibition: Incorporating novel strategies into therapy.
Vincent Miller
2c.
Case Study: How do we best utilize molecular biomarkers and testing beyond EGFR-mutation testing for optimal use of personalized EGFR-directed inhibition?
Fred Hirsch
2d.
Additional Case Studies
Corey Langer
2e.
Roundtable Panel Discussion and Q & A
Faculty and Learners
Session 3: PERSONALIZING LUNG CANCER TARGETS WITH CHEMOTHERAPY
Chair: Paul Bunn
3a.
Enlisting the immune system and vaccines for NSCLC patients
Paul Bunn
3b.
Case Study: Switch maintenance therapy: What are the options for improving outcomes in NSCLC patients using chemotherapy, targeted therapy or both?
Roy Herbst
3c.
Additional Case Studies
Edward Garon
3d.
Case Study: Best practices and NSCLC outcomes with optimal clinical strategies using radiation plus chemotherapy: What is optimal?
Walter Curran
3e.
Roundtable Panel Discussion and Q & A
Faculty and Learners
3f.
Case Study: What are best clinical practices for NSCLC relapses after initial and subsequent therapies?
Barbara Gitlitz
3g.
Case Study: Improving outcomes using novel and emerging strategies with chemotherapy: What are the new options for small cell lung cancer and NSCLC?
Mark Socinski
3h.
Case Study: How do we perform more effective biomarker testing for matching NSCLC patients with optimal therapy for maintenance of disease remission and after relapsed NSCLC?
Philip Mack
3i.
Roundtable Panel Discussion and Q & A
Faculty and Learners
Session 4: PERSONALIZING ANGIOGENESIS-TARGETED THERAPY
Chair: Joan Schiller
4a.
Case Study: Rethinking patient eligibility for anti-angiogenic-based regimens in first-line therapy for advanced or metastatic non-squamous NSCLC: Are we maximizing our therapeutic options to help more patients?
Alan Sandler
4b.
Case Study: Examining the optimal clinical applications of anti-angiogenic-based NSCLC strategies to help more patients in the maintenance and second-line settings?
John Heymach
4c.
Roundtable Panel Discussion and Q & A
Faculty and Learners
Session 5: EMERGING NSCLC TARGETS, NOVEL STRATEGIES AND OPPORTUNITIES FOR ENROLLMENT IN CLINICAL TRIALS
Chair: Roy Herbst
5a.
Case Study: Histology and beyond: Personalizing first-line strategies employing chemotherapy for improving NSCLC outcomes
George Simon
5b.
Case Study: New developments for bone metastases: Do we have two viable options?
Corey Langer
5c.
NSCLC New pathways and targets: HER1, c-MET, EML4/ALK, PARP, Clusterin, HDAC, IGF-1R. How can inhibiting these improve outcomes?
Suresh Ramalingam
5d.
Roundtable Panel Discussion and Q & A
Faculty and Learners

Educational Objectives

Physician

Based on the data identified in the Needs Assessment and Physician Practice Gap Identification, the following Learning Objectives have been developed for this CME/CE activity:

  1. Review the new predictive and prognostic NSCLC biomarker testing guidelines of the College of American Pathologists and the International Association for the Study of Lung Cancer (CAP/IASLC).
  2. Employ the new and evolving NSCLC algorithms.
  3. Order EGFR mutation test data for all eligible NSCLC patients.
  4. Utilize histology data for improving NSCLC outcomes.
  5. Explain the recent data regarding the optimal combination of radiation therapy and systemic therapy for NSCLC patients.
  6. Evaluate the eligibility of nonsquamous NSCLC patients for targeting angiogenesis.
  7. Describe the evidence-based strategies for retargeting EGFR in NSCLC patients who relapse.
  8. Differentiate the risks and benefits of novel and emerging chemotherapy strategies for lung cancer.
  9. Review the recent data regarding Spiral CT scans for identifying persons at high-risk for developing NSCLC.
  10. Describe the opportunities for enrolling NSCLC patients in clinical trials with emerging targets and novel strategies.

Pharmacist

Based on the data identified in the Needs Assessment and Physician Practice Gap Identification, the following Learning Objectives have been developed for this CME/CE activity:

  1. Recognize the new predictive and prognostic NSCLC biomarker testing guidelines of the College of American Pathologists and the International Association for the Study of Lung Cancer (CAP/IASLC).
  2. Recall the new and evolving NSCLC diagnostic and treatment algorithms.
  3. Define the EGFR mutation testing procedures for eligible NSCLC patients.
  4. Recognize how histology data improves NSCLC outcomes.
  5. Reproduce the recent data regarding the optimal combination of radiation therapy and systemic therapy for NSCLC patients.
  6. State the eligibility of nonsquamous NSCLC patients for targeting angiogenesis.
  7. Define the evidence-based strategies for retargeting EGFR in NSCLC patients who relapse following initial therapy.
  8. Recognize the risks and benefits of novel and emerging chemotherapy strategies for lung cancer.
  9. Recall the recent data regarding the risks and benefits of Spiral CT scans for identifying persons at high-risk for developing NSCLC.
  10. State the opportunities for enrolling NSCLC patients in clinical trials with emerging targets and novel strategies.

Target Audience and CME/CE Information

Target Audience
This activity is designed to meet the educational needs of, and help close Practice Gaps of medical oncologists, hematologists, pharmacists, nurses, nurse practitioners, radiation oncologists, surgical oncologists, pathologists, and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer, including physician assistants and fellows. Lung cancer is treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are invited to attend.

CME Accreditation & Credit Designation
The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Biomedical Learning Institute designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Biomedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-12-001-L01-P
Credits: 7.5 hours (0.75 ceu)
Type of Activity: Knowledge

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8 hours of Category 1 credit for attending this symposium.

Nurse Practitioners, nurses, and Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.



CME Certificate or Certificate of Participation
The relevant section(s) of the Evaluation Form pertaining to the session(s) of the enduring materials you have viewed or listened to, and the Request for Credit Form must be completed and submitted to the Biomedical Learning Institute following your participation in the enduring material educational activity to obtain CME/CE credit. Physicians and other participants will be able to print their certificates after they complete these Forms.

Faculty & Disclosures

It is the policy of the Biomedical Learning Institute to ensure that all of its educational activities and materials are of the highest quality, and are balanced, objective, independent, free of commercial bias, and planned and developed with scientific rigor with strict adherence to all Accreditation Council for Continuing Medical Education (ACCME) rules and policies. The BMLI evaluates all content, faculty and faculty disclosures for any potential conflicts of interest. Should any conflicts of interest be identified these conflicts are resolved in advance of the educational activity by independent peer reviewers who are experts in the subjects of the educational activity.

All faculty and BMLI staff participating in the content, planning or implementation of an educational CME/CE activity are required to disclose to the audience of the educational activity any relevant financial relationships or interests and to assist in the resolution of any conflict of interest that may arise from the relationship(s) or interest(s). It is also the policy of the BMLI to require all faculty presenters to make a meaningful disclosure to the audience of their discussions of unlabeled or FDA unapproved drugs, products, tests or devices. This information will be available as part of the educational activity and related material.

The following faculty and BMLI staff have reported real or potential relevant conflicts of interest and these conflicts have been resolved, prior to this educational activity through a peer-review process by two medical oncologists who have had no affiliation with this educational activity other than the peer review process.

Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director, USA
International Association for the Study of Lung
Cancer (IASLC)

Consulting Fees: Merrimack
Ownership Interest: Merrimack
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
Roy S. Herbst, MD, PhD
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Smilow Cancer Hospital at Yale-New Haven
Yale School of Medicine
New Haven, CT

Consultant: Abraxis, AstraZeneca, Eli Lilly, Roche, GlaxoSmithKline, Genentech
Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group (RTOG)

Consulting Fees: Bristol-Myers Squibb, ImClone, Sanofi-Aventis, Pfizer, Lilly, Amgen, AstraZeneca, Novartis, Genentech (Roche), Bayer/Onyx, Abraxis (Celgene), Abbott, Morphotek, Biodesix, Clarient, CarisDX and Ariad
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Lilly, Genentech, OSI, ImClone, Bristol-Myers Squibb
Contracted Research: Bristol-Myers Squibb, ImClone, Pfizer, Lilly, Genentech (Roche), OSI, and GSK
Expert Faculty
Walter J. Curran, MD, FACR
Professor and Chair
Department of Radiation Oncology Emory School of Medicine Chief Medical Officer
Winship Cancer Institute
Atlanta, GA
Chairman, Radiation Therapy Oncology Group (RTOG)

Consulting Fees: Amgen, Lilly, BMS and ImClone
Edward B. Garon, MD
Associate Professor of Medicine
Department of Medicine, Hematology/Oncology
Jonsson Comprehensive Cancer Center
Thoracic Oncology Program Area
University of California at Los Angeles School of Medicine
Los Angeles, CA

Consulting Fees: Boehringer-Ingelheim
Barbara J. Gitlitz, MD
Associate Professor of Clinical Medicine
Department of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech, Lilly and BMS
Fred R. Hirsch, MD, PhD
Professor, Division of Medical Oncology
University of Denver School of Medicine
Denver, Colorado

Consulting Fees: Genentech, Lilly, Celgene, Astellas (OSI) and Merck Serono
Contracted Research: Celgene, Astellas (OSI)
John V. Heymach, MD, PhD
Professor of Thoracic Head/Neck Medical Oncology
Professor of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Consulting Fees: Genentech
Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center
Physician-in-Chief,
Smilow Cancer Hospital, Yale-New Haven
New Haven, CT

Receipt of Intellectual Property Rights/Patent Holder: Partners HC
Consulting Fees: Merck, Boehringer-Ingelheim, and SuperGen
Ownership Interest: Infinity
Philip C. Mack, PhD
Associate Adjunct Professor
Co-leader Molecular Pharmacology
UC Davis Cancer Center
Sacramento, CA

Consulting Fees: BMS
Contracted Research: Merck, TriAct Therapeutics and BMS
Vincent A. Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Receipt of Intellectual Property Rights/Patent Holder: Patent for T790M issued and licensed to MolecularMD
Consulting Fees: Boehringer-Ingelheim, Clovis, Genentech, OSI and Astellus
I intent to reference unlabeled/unapproved uses of drugs or products in my presentation (Afatinub and cetuximab in NSCLC and AUY-922 in NSCLC)
Suresh S. Ramalingam, MD
Director
Division of Medical Oncology
Associate Professor
Emory University School of Medicine
Atlanta, Georgia

Consulting Fees: Aveo, Abbott, Pfizer, Lilly and Genentech
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR
Co-Chair, Eastern Cooperative Oncology Group (ECOG)

Consulting Fees: Abraxis, Agennix, Allos Therapeutics, Boehringer-Ingelheim, Celgene, Lilly, Genentech, GSK, Hoffman-LaRoche, NewLink Genetics, Novartis, OxiGene, Pfizer, Roche, VeriStrat (Biodesix)
Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Lilly, Genentech, Quintiles
Contracted Research: Abraxis, Lilly, Pfizer and Synta
Other (Legal Consulting): Agennix, Boehringer-Ingelheim, BMS, Celgene, Chugai (Roche), Daiichi-Sankyo, Lilly, Genentech, GSK, OxiGene, Roche, and Quintiles
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
Joan H. Schiller, MD
Professor & Division Chief,
Hematology-Oncology
Deputy Director, Harold C. Simmons Cancer Center
Andrea L. Simons Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Dallas, TX
Chair, Lung Committee, Eastern Cooperative Oncology
Group (ECOG)

Consulting Fees: Lilly and Celgene
Contracted Research: Celgene and Genentech
George R. Simon, MD, FACP, FCCP
Associate Professor of Medicine & Oncology
The Burtschy Family Endowed Chair in Cancer Research
Assistant Director, Clinical Investigations,
Hollings Cancer Center
Division of Hematology/Oncology,
Department of Medicine
Medical University of South Carolina
Charleston, SC

I have no real or apparent conflicts of interest to report.
Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section,
Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
Pittsburgh, PA

Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech and Lilly
Contracted Research: Genentech, Lilly, Synta, Pfizer and Celgene
I intend to reference unlabeled/unapproved uses of drugs or products in my presentation.
Danielle Shafer, MD (Peer Reviewer)
I have no real or apparent conflicts of interest to report.
Steve Madison, RPh, MBA (BMLI Manager/Peer Reviewer)
I have no real or apparent conflicts of interest to report.
Marie Alexander (BMLI Planner)
I have no real or apparent conflicts of interest to report.
Phillip Renner (BMLI Planner)
I have no real or apparent conflicts of interest to report.


This educational activity has been independently peer-reviewed.

Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.

The Biomedical Learning Institute (OLC) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI . Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.

Educational Grants
Genentech Bio
Lilly
Boehringer Ingelheim
Celgene
Astellas
EMD Serono
Bristol-Myers Squibb
Daiichi Sankyo
Biodesix
Lung Cancer Alliance
Oncology Business Review
© 2012 Biomedical Learning Institute
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.